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Metastasis is a crucial hallmark of cancer progression, which involves numerous factors including the degradation of
the extracellular matrix (ECM), the epithelial-to-mesenchymal transition (EMT), tumor angiogenesis, the development
of an inflammatory tumor microenvironment, and defects in programmed cell death. Programmed cell death, such
as apoptosis, autophagy, and necroptosis, plays crucial roles in metastatic processes. Malignant tumor cells must
overcome these various forms of cell death to metastasize. This review summarizes the recent advances in the
understanding of the mechanisms by which key regulators of apoptosis, autophagy, and necroptosis participate in
cancer metastasis and discusses the crosstalk between apoptosis, autophagy, and necroptosis involved in the
regulation of cancer metastasis.
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Metastasis is a key step of cancer progression that indi-
cates a more advanced stage and a poorer prognosis. Mul-
tiple cellular processes, including the degradation of the
extracellular matrix (ECM), the epithelial-to-mesenchymal
transition (EMT), tumor angiogenesis, the development of
an inflammatory tumor microenvironment, and the dys-
function of programmed cell death machinery, have been
demonstrated to be essential for cancer metastasis [1].
Any mistakes made by a metastatic cell during these cellu-
lar events may lead to cell death. Therefore, the regulation
of cell death is critical for cancer cells to survive during
metastasis.
Programmed cell death is defined as regulated cell
death mediated by an intracellular program. Apoptosis
was originally thought to be the only form of pro-
grammed cell death. However, in the last decade, pro-
grammed cell death has expanded to include autophagy
and a form of necrosis termed necroptosis (programmed
necrosis). Programmed cell death, especially apoptosis* Correspondence: yangzuozhang@163.com
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unless otherwise stated.and necroptosis, are natural barriers that restrict malig-
nant cells from surviving and disseminating. However,
cancer cells evolve various strategies to evade pro-
grammed cell death by generating genetic mutations or
epigenetic modifications in the key modulators of pro-
grammed cell death pathways.
In this review, we summarize the interplay (or the
link) of the different form of program cell death with
cancer metastasis, and we anticipate future challenges
and unsolved questions related to these topics.Review
An introduction to cancer metastasis
Cancer metastasis is a complex process that can be di-
vided into five major steps: the first step, invasion, is
characterized by increased cell motility caused by alter-
ations in cell-cell and cell-ECM interactions [2]. The
second step is intravasation, in which tumor cells escape
from the primary site and migrate into circulation systems.
The third step, dissemination, is the process in which ma-
lignant cells travel through the circulation systems to
reach a capillary bed, where the cancer cells adhere to the
vessel walls or are detained at these sites because of size
constraints. The fourth step is extravasation, in which
cancer cells permeate the vessels to enter their destin-
ation organs. Colonization is the final step, in which
metastatic cells proliferate and form micrometastases oris an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sidered as a two-phase process according to a new perspec-
tive [3]: the first phase involves the physical translocation
of a cancer cell to a distant organ, whereas the second
phase encompasses the process of the development of the
cancer cells into a metastatic lesion at the distant site. Typ-
ically, the initial steps of metastasis (invasion, intravasation,
dissemination, and extravasation) proceed at a very high ef-
ficiency, but the final step, colonization, is less efficient. It
has been estimated that only ~0.01% of circulating tumor
cells ultimately produce macrometastases [4]. This ineffi-
ciency may be closely related to the activation of cell death
machinery by various stresses before or after the cells reach
a new environment. Such stresses include the loss of cell-
cell contacts, the recognition and destruction of the cancer
cells by the immune system, and the lack of necessary
growth factors, all of which may trigger programmed cell
death, including apoptosis, autophagy and necroptosis [4].
Apoptosis and cancer metastasis
Apoptosis is a type of programmed cell death that is
characterized by cell membrane blebbing, cell shrinkage,
nuclear fragmentation, chromatin condensation, and
chromosomal DNA fragmentation [5,6]. There are two
basic apoptotic signaling pathways: the extrinsic and the
intrinsic pathways [7]. The intrinsic apoptotic pathway is
activated by various intracellular stimuli, including DNA
damage, growth factor deprivation, and oxidative stress.
It relies on the formation of a complex termed the apopto-
some, composed of procaspase-9, apoptotic protease-
activating factor (Apaf-1), and cytochrome c. A series of
Bcl-2 family members, such as Bax, Bak, Bcl-2, and Bcl-xL,
control the release of cytochrome c by regulating mito-
chondrial membrane permeabilization. The extrinsic path-
way of apoptosis is initiated by the binding of death ligands
[e.g., Fas ligand (FasL), TNF-related apoptosis inducing lig-
and (TRAIL), and TNF-α] to death receptors of the TNF
receptor superfamily. This interaction is followed by the as-
sembly of the death-inducing signaling complex (DISC),
which consists of the Fas-associated death domain (FADD)
protein and procaspase-8/10. DISC then either activates
downstream effector caspases (caspase-3, 6 and 7) to dir-
ectly induce cell death or cleaves the Bcl-2 family member
Bid into tBid to activate the mitochondria-mediated intrin-
sic apoptotic pathway [7]. Numerous factors, such as p53,
cellular inhibitor of apoptosis proteins (cIAPs), and NF-κB,
have been reported to be involved in the regulation of
apoptotic pathways [2,8]. Many small molecules targeting
apoptotic pathways have been developed for cancer ther-
apy. For example, ABT-737, ABT-263, and GX15-070 have
been reported to act on Bcl-2 family members; GDC-0152,
birinapant, AT-406, and HGS-1029 have been designed to
antagonize cIAPs, among the most promising targets for
anti-cancer agent development; and Nutlins, MI-219 andMI-77301 have been shown to antagonize murine double-
minute 2 (MDM2), a critical negative regulator of p53 that
promotes p53 ubiquitination and degradation [9,10].
Apoptosis may block metastatic dissemination by kill-
ing misplaced cells. Thus, apoptosis serves as an import-
ant process for inhibiting metastasis. The success of the
metastatic process relies on the ability of malignant cells
to escape apoptosis. Apoptotic resistance is indispensable
for all steps of metastatic progression, but the most critical
step may be the resistance to cell death induced by the loss
of cell-cell and cell-ECM contacts [8]. The detachment of
cells from the ECM induces a type of apoptosis termed
anoikis. Numerous reports have demonstrated that anoikis
resistance is frequently observed in metastatic cells [11-14].
For instance, TrkB, a neurotrophic tyrosine kinase receptor,
was found to act as a specific suppressor of caspase-
associated anoikis in non-malignant epithelial cells. TrkB
activates the phosphatidylinositol-3-OH kinase (PI3K)/pro-
tein kinase B (PKB) pathway to promote the formation of
large cellular aggregates that survive and proliferate in sus-
pension, and these cellular aggregates develop into rapidly
growing tumors that infiltrate lymphatics and blood vessels
to colonize a distant organ in mice [13]. In addition, signal
transducer and activator of transcription 3 (STAT3) was
found to play a role in conferring anoikis resistance to pan-
creatic cancer cells and in promoting metastasis. Enhanced
STAT3 expression and phosphorylation at Tyr 705 have
been associated with the anoikis resistance and the meta-
static capacity of pancreatic cells [14].
In addition, metastatic cells must develop a mechan-
ism to evade cell death resulting from recognition and
destruction by cytotoxic lymphocytes such as natural
killer (NK) cells. Furthermore, tumor cells must survive
in the environment of reactive oxygen species (ROS)
produced by endothelial cells when crossing the vessel
or tissue barrier during the extravasation step [15,16]. Fi-
nally, malignant cells must tolerate hypoxic conditions
and proliferate in an environment lacking the necessary
cytokines for growth to achieve successful colonization
at their destination sites [8,17].
Even after the successful formation of micrometas-
tases, macroscopic tumors may not develop because of
dormancy [18]. The nature of dormancy remains to be
elucidated. One hypothesis states that the rate of prolif-
eration is balanced by the rate of apoptosis such that no
net tumor growth occurs [19], whereas another hypoth-
esis states that dormant cells neither proliferate nor
undergo apoptosis [20]. However, genetic variation and/
or environmental stimulation may drive cells out of dor-
mancy and into an anti-apoptotic, highly proliferative
state [21].
In the Table 1, we summarize the roles of the known
major apoptotic factors that participate in cancer
metastasis.
Table 1 Roles of the major known apoptotic participators in cancer metastasis
Gene Description Association with cancer metastasis (representative examples)
1. Caspases and caspase inhibitors
Caspase-8 Initiator caspase Caspase-8 knockout Th-MYCN mice developed advanced neuroblastoma
with bone marrow metastasis [22].
Caspase-10 Initiator caspase Caspase-10 mutations were identified in NSCLC patients with lymph node
metastases [23].
Caspase-3 Effector caspase The caspase-3 protein level negatively correlated with lymph node
metastasis in NSCLC patients [24]. Another report described an inverse
association between caspase-3 expression and lymph node metastasis in
gastric carcinomas, although most of the caspase-3 protein was
not activated [25].
IAPs (XIAP, survivin,
and cIAP1/2)
Caspase inhibitors Increased levels of the apoptosis inhibitor protein XIAP contributed to the
anoikis resistance of circulating human prostate cancer metastatic precursor
cells [26]. A recent study showed that intermolecular cooperation between
XIAP and survivin stimulated tumor cell invasion and promoted metastasis
and that this pathway was independent of the IAP-mediated inhibition
of cell death [27].
DAPK Upstream regulator of capases-3/6/7 DAPK downregulation or inactivation was observed in several metastatic
cancers. In certain cases, DAPK downregulation correlated with
metastatic recurrence [28].
2. Intrinsic apoptotic pathway
Apaf-1 Key apoptosome component Apaf-1 gene haploinsufficiency correlated with colorectal carcinoma
progression and hepatic metastasis [29].
Bcl-2 Controls mitochondrial
membrane permeability
The pulmonary metastatic burden was dramatically augmented in mice
inoculated with Bcl-2 transfectants [30]. Elevated nuclear expression of
Bcl-2 correlated with increased hepatocellular carcinoma metastasis [31].
Bcl-xL Controls mitochondrial
membrane permeability
Bcl-xL overexpression caused apoptosis resistance and acted as an
enhancer of metastasis but not primary tumor growth [32].
Bax Same as above Bax expression was markedly decreased in metastatic colorectal
cancer cells [33]. Bax inhibitor-1 enhanced cancer metastasis [34].
Maspin Serine protease inhibitor Maspin expression was reduced in brain-metastasized breast
cancer cells [35]. Decreased expression of maspin restricted the
growth and metastasis of colorectal cancer xenografts in mice [36].
3. Extrinsic apoptotic pathway
FADD Key adaptor that transmits death
signals mediated by death receptors
Somatic mutations in FADD were observed at a higher frequency in
metastatic NSCLC tumors than in the corresponding primary tumors [23].
High FADD expression was associated with regional and distant
metastasis in squamous cell carcinoma of the head and neck [37].
FasL and Fas Key death ligand and its
receptor, respectively
Fas-sensitive melanoma clones were highly tumorigenic but were rarely
metastatic in wild-type syngeneic mice. However, in FasL-deficient mice,
both the incidence and the number of metastases were increased [38].
The ability of osteosarcoma cells to form lung metastases inversely
correlated with cell surface Fas expression [39].
sFas and DcR3 soluble Fas and FasL decoy
receptor, respectively
In gastric carcinomas, the serum DcR3 levels closely correlated with
the tumor differentiation status and the TNM classification [40].
TRAIL TNF family death ligand Mice depleted of NK cells or treated with a TRAIL-blocking antibody
exhibited a significant increase in spontaneous liver metastasis [41,42].
DR4 and DR5 Death receptors for TRAIL TRAIL receptor deficiency in mice enhanced lymph node metastasis
of squamous cell carcinoma without affecting primary tumor development [43].
DcR1, DcR2, and OPG TRAIL decoy receptors The expression of decoy receptors in tumor cells served as an
alternate mechanism to resist TRAIL-induced apoptosis [42].
4. Regulators of apoptotic pathways
JNKs Dual-role regulators of apoptosis JNKs induced or inhibited cancer cell apoptosis in a manner that was
dependent on the cell type, the stimulus, the duration of JNK activation
and the activity of other pathways [44]. JNKs served dual roles as both
suppressors and promoters of cancer metastasis [45-47].
NF-κB Transcription factor Activated NF-κB transactivated many anti-apoptotic genes, including
Bcl-2, Bcl-xL, survivin, cIAP-1/2, and c-FLIP, as well as many
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Table 1 Roles of the major known apoptotic participators in cancer metastasis (Continued)
angiogenesis-related genes [48]. NF-κB activity was closely
associated with cancer metastasis [49,50].
p53 and p63 Transcription factors p53 upregulated pro-apoptotic genes, such as Fas, DR5, Bax, Bak and Apaf-1,
and repressed anti-apoptotic effectors, such as Bcl-2, Bcl-xL and survivin [51].
p53 loss or mutation promoted tumor metastasis [44]. The loss of p53 led to
invasion and lymph node metastasis of carcinogen-induced colorectal tumors [52].
By interacting with mutant p53, p63 suppressed tumorigenesis and metastasis [53,54].
TGF-β, TβRI/II,
and SMADs
TGF-β pathway genes The SMAD complex transactivated a series of apoptosis-related genes [55-58].
TGF-β signals also induced apoptosis via the activation of the ARTS and Daxx-JNK
pathways [59,60]. Prior to tumor initiation and the early stages of progression, TGF-β
signaling acted as a tumor suppressor; however, at later stages, it often
promoted metastasis [61].
MMPs Prominent family of proteinases MMPs played roles in the regulation of ECM turnover, cancer cell migration,
cell growth, inflammation, and angiogenesis [62]. They also interfered with
the induction of apoptosis in malignant cells via the cleavage of ligands or
receptors in the apoptotic pathways [63-65].
Note: NSCLC, non-small-cell lung cancer; Apaf-1, apoptotic protease-activating factor; IAPs, cellular inhibitors of apoptosis proteins; XIAP, X-linked inhibitor of
apoptosis; DAPK, death-associated protein kinase; FADD, Fas-associated death domain-containing protein; sFas, soluble Fas; DcR3, decoy receptor 3; TRAIL,
TNF-related apoptosis-inducing ligand; DcR1, decoy receptor 1, also referred to as TRAIL-R3; DcR2, decoy receptor 2, also referred to as TRAIL-R4; OPG,
osteoprotegerin; DR4, death receptor 4; TβR I/II, TGF-β receptor I/II; MMPs, matrix metalloproteinases; JNK, c-Jun N-terminal kinases.
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c-Jun N-terminal kinases (JNK), TGF-β, and matrix me-
talloproteinase (MMP) pathways play dual roles in apop-
tosis and metastasis. JNKs, a subgroup of the MAP
kinase superfamily, are indispensable for both cell prolif-
eration and apoptosis. Whether the activation of JNKs
leads to cell proliferation or apoptosis is dependent on
the cell type, the nature of the death stimulus, the dur-
ation of its activation and the activities of other signaling
pathways [66]. In the absence of NF-κB activation,
enhanced JNK activation contributes to TNF-α induced
apoptosis. JNK is also a critical mediator of UV radiation-
induced apoptosis. JNK promotes apoptosis via different
mechanisms. Activated JNK translocates to the nucleus
and transactivates c-Jun and other transcription factors
(e.g., p53), which further transactivate various pro-
apoptotic genes, such as Fas-L, Bak, and p53-upregulated
modulator of apoptosis (PUMA) [67]. In addition, JNKs
contribute to apoptosis by modulating the activities of
mitochondrial pro- and antiapoptotic proteins via distinct
phosphorylation events. However, JNK inhibits apoptosis
in IL-3-dependent hematopoietic cells via the phosphoryl-
ation and antagonism of the proapoptotic Bcl-2 family
protein BAD [66].
It was reported that JNK signaling prevented the pro-
gression of invasive adenocarcinoma in PTEN−/− pros-
tate cancer. Mice exhibiting JNK deficiency in the
prostate epithelium (JNK and PTEN double-deficient
mice) develop androgen-independent metastatic prostate
cancer more rapidly than control (PTEN-deficient) mice.
In addition, JNK-deficient progenitor cells exhibited in-
creased proliferation and tumorigenic capacity compared
with progenitor cells from control prostate tumors [45].
A group reported that Notch and myocyte enhancer
factor 2 (Mef2) cooperated to promote proliferation andmetastasis via JNK signal activation and the consequent
induction of the invasion marker MMP1 in a Drosophila
model [46]. Another study showed that receptor for ad-
vanced glycation end products (RAGE) splice variant 1
inhibited tumor formation, cell invasion, and angiogen-
esis induced by RAGE ligand signaling, which was
closely related to the strong suppression of JNK by this
splice variant protein [47].
The transforming growth factor-β (TGF-β) family pro-
teins bind to cell surface type I and type II serine/threo-
nine kinase receptors (TGFβRI and TGFβRII, respectively)
and SMAD mediators to regulate many biological pro-
cesses. Numerous studies have reported roles of the TGF-β
pathway in apoptosis. Many pro-apoptotic genes are under
the control of the SMAD transcription-regulating com-
plexes. For example, TGF-β-inducible early response gene
(TIEG1) [56], death-associated protein kinase (DAPK) [57],
and SH2 domain-containing inositol-5-phosphatase (SHIP)
[58] have been shown to be essential for the suppression of
cell proliferation and the induction of apoptosis in many
cell types. Another mechanism of TGF-β-related apoptosis
is the induction of the mislocalization of a mitochondrial
septin family member ARTS. Upon translocation, ARTS
binds to and inactivates XIAP, a key inhibitor of apoptosis,
which leads to the activation of caspase-3 and apoptosis
[59]. In addition, TGF-β signals induce the death associated
protein (Daxx)-JNK pathway to induce apoptosis under
certain circumstances [60].
The roles of the TGF-β signaling pathway in cancer
development are uncertain [61]. Prior to tumor initiation
and during the early stage of progression, TGF-β acts as
a tumor suppressor via cell cycle arrest and the induc-
tion of apoptosis; however, at advanced stages, TGF-β
often acts as a tumor promoter via the acceleration of
the EMT, invasion, and angiogenesis, the maintenance of
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environment [61]. Interestingly, TGF-β is expressed at
high levels during the late stages of tumor progression in
many human cancers, but paradoxically, the TGF-β path-
way is frequently mutationally inactivated in cancer cells.
Further studies revealed that elevated TGF-β expression
played an important role in promoting stromal cells to se-
cret cytokines that favor cancer cell metastasis [68].
Matrix metalloproteinases (MMPs) constitute one of
the most prominent families of proteinases associated
with tumor metastasis. MMPs interfere with the induc-
tion of apoptosis in malignant cells via the cleavage of
ligands or receptors in apoptotic pathways [62]. For in-
stance, MMP-7 was reported to cleave membrane-bound
FasL on doxorubicin-treated cancer cells, thereby attenu-
ating apoptosis and increasing the resistance of these cells
to chemotherapy [63,64]. MMP-13 was shown to be in-
volved in the shedding of nerve/glial antigen 2 (NG2), a
novel anoikis receptor, thereby contributing to the attenu-
ation of anoikis [65].
Autophagy and cancer metastasis
Autophagy is an evolutionarily conserved catabolic process
in which intracellular membrane structures package pro-
tein complexes and organelles to degrade and renew these
cytoplasmic components. It is thus critical for cell growth
regulation and internal homeostasis [69]. Autophagy is
physiologically a cellular strategy and mechanism for sur-
vival under stress conditions. When over-activated under
certain circumstances, excess autophagy results in cell
death. To date, three types of autophagy have been identi-
fied: macroautophagy, microautophagy, and chaperone-
mediated autophagy. We only discuss macroautophagy in
this review; therefore, henceforth, "autophagy" specifically
refers to macroautophagy. Autophagy is a multi-step
process that includes nucleation, elongation, and autopha-
gosome and autolysosome formation and that is executed
by a series of highly conserved genes termed autophagy-
related genes (ATGs) [70]. Autophagy is often triggered by
nutrient deprivation, ROS, hypoxia, drug stimuli, and
endoplasmic reticulum (ER) stress via complex signal
transduction pathways. Alterations in the autophagy ma-
chinery may lead to diverse pathological conditions, such
as neurodegeneration, ageing, and cancer [71]. Mamma-
lian target of rapamycin complex 1 (mTORC1), class I
PI3K, AKT, class III PI3K, Beclin-1 and p53 are critical
components of the autophagic pathway that have become
major targets of autophagy-related drug design. Numerous
small molecules have been found to target these com-
ponents and to play a role in tumor treatment. For ex-
ample, rapamycin and its derivatives (i.e., rottlerin,
PP242 and AZD8055) target the PI3K/AKT/mTOR
signaling pathway to induce autophagy; spautin-1 and
tamoxifen regulate Beclin-1 activity to inhibit andpromote autophagy, respectively; and oridonin and
metformin trigger p53-mediated autophagy and cell
death [72].
The role of autophagy in cancer metastasis is complex,
as reports have indicated both pro-metastatic and anti-
metastatic roles of autophagy. Stage-specificity may
affect the cellular response to autophagy during cancer
metastasis [73]. During the early stage of cancer metas-
tasis, autophagy may act as a suppressor of metastasis by
restricting tumor necrosis and inflammatory cell infiltra-
tion and by alleviating oncogene-induced senescence.
These processes may help to reduce the invasion and
dissemination of cancer cells from the primary site. Dur-
ing the advanced stages of metastasis, autophagy tends
to act as a promoter of metastasis by promoting ECM-
detached metastatic cell survival and colonization in a
distant site and by inducing metastatic cells that fail to
establish contact with the ECM in the new environment
to enter dormancy.
The anti-metastatic role of autophagy
Necrosis frequently occurs inside a tumor due to hyp-
oxia and metabolic stress, which enables inflammatory
cells, especially macrophages, to infiltrate tumor sites
and which generates a favorable microenvironment for
tumor metastasis [74,75]. Autophagy facilitates the sur-
vival of tumor cells under metabolic stress and hypoxic
conditions, thereby effectively reducing tumor necrosis
and subsequent immune cell infiltration and metastasis
[76]. In addition, autophagy regulates the selective re-
lease of the immune modulator high-mobility group B1
(HMGB1) by the tumor cells that are destined to die
[77,78]. Once released, HMGB1 activates dendritic cells
by engaging Toll-like receptor 4, which triggers an intense
antitumor immune response and restricts metastasis
[79,80]. Prophylactic treatment with the TLR4 and TLR9
agonist complex triggered anti-metastatic immunity and
impaired tumor metastasis by inducing the autophagy-
associated death of melanoma cells via IFN-γ/STAT1 acti-
vation. The induction of autophagy via the injection of
rapamycin with or without the TLR4/9 agonist complex
into the tumor attenuated metastasis [81].
ATG5, a key regulator of autophagy, was found to be
downregulated in primary melanomas compared to be-
nign nevi, and this decrease in ATG5 expression is ac-
companied by a reduction in the expression of LC3 and
in basal autophagy. It was shown that patients express-
ing low levels of ATG5 in their tumors exhibited
decreased progression-free survival according to a follow-
up of 158 primary melanoma patients. Mechanically, redu-
cing ATG5 expression may promote cell proliferation by
preventing oncogene-induced senescence and may con-
tribute to the progression of early-stage cutaneous melan-
oma [82].
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pathway that negatively regulates autophagy and that
promotes cancer progression. Recent studies have sug-
gested that PI3K/Akt/mTOR signaling is upregulated in
30-50% of prostate cancers, often due to the loss of
PTEN. It has been reported that molecular changes in
the PI3K/Akt/mTOR signaling pathway are implicated
in the elevation of the tumor stage and grade and the
risk of recurrence [83]. PTEN mutations and deletion
within primary tumors have been associated with an in-
creased risk of metastasis, and early targeting of PTEN
may prevent metastasis [84]. Genistein, an Akt inhibitor,
has been shown to play a role in decreasing the inci-
dence of lung metastasis in an orthotopic prostate model
using PC-3 cells [85]. Mechanically, increasing autopha-
gic flux by inhibiting the PI3K/Akt/mTOR pathway may
promote the apoptosis of cancer cells [86,87].
In addition, a unique death modality termed autopha-
gic cell death plays a role in impeding cancer metastasis.
Autophagic cell death refers to cell death caused by au-
tophagy rather than cell death with autophagy. Thus, the
ultimate cell death process of autophagic cell death is
executed by over-activated autophagic flux rather than
apoptosis or necroptosis. The genetic or drug-based in-
hibitors of autophagy, but not apoptosis or necroptosis
inhibitors, rescue this type of cell death [88,89]. It is
known that there is a complex relationship between
apoptosis and autophagy. Typically, autophagy antago-
nizes apoptosis, and as a feedback response, apoptosis-
related caspase activation reduces the autophagic process.
However, autophagy can also trigger apoptosis under cer-
tain circumstances via the activation of caspase-8 and the
depletion of endogenous apoptosis inhibitors [90-92]. Au-
tophagic cell death does not include autophagy-induced
apoptosis or necroptosis. Several studies have suggested a
potential relationship between autophagic cell death and
cancer metastasis. For example, one study showed that
blocking the CXCR4/mTOR signalling pathway induced
autophagic cell death and the anti-metastatic properties of
peritoneally disseminated gastric cancer cells [93].
The pro-metastatic role of autophagy
Acquiring the ability to survive and proliferate in the ab-
sence of the ECM while disseminating through the circu-
lation systems and colonizing a distant site is necessary for
cancer cell metastasis [94,95]. Otherwise, cancer cells die
of anoikis (a specific type of apoptosis induced by the loss
of ECM attachment). The constitutive activation of pro-
survival signals such as PI3K, Ras–ERK, NF-κB, and Rho
GTPase often occurs in cancer cells, thereby antagonizing
anoikis. This antagonism can be achieved via the autocrine
secretion of growth factors or the overexpression of recep-
tor tyrosine kinases [13,96]. Accumulating evidence sug-
gests that autophagy also provides a mechanism formatrix-detached pre-metastatic tumor cells to avoid anoi-
kis [97,98]. In a hepatocellular carcinoma (HCC) lung me-
tastasis model, the inhibition of autophagy (via the
lentivirus-mediated silencing of BECN1 and ATG5) mark-
edly decreased the pulmonary metastasis of HCC cells.
Further investigation indicated that the inhibition of au-
tophagy did not affect cell invasiveness, migration or the
EMT but attenuated the anoikis resistance and lung
colonization of HCC cells [99]. Another study showed that
autophagy was induced by either matrix detachment or β1
integrin inhibition [100]. Autophagy in ECM-disrupted
cells may compensate for the loss of extrinsic signals that
promote and maintain nutrient and energy metabolism.
Under these conditions, autophagy might delay the on-
set of apoptosis, providing cells with additional time to
re-attach to an appropriate ECM. In a rapidly growing
tumor with high energy and biosynthesis requirements,
detachment-induced autophagy undoubtedly increases the
survival of the cells deprived of ECM contact [96,97].
Aside from ECM disruption, increased metabolic and
oxidative stresses in cancer cells and adverse environ-
mental stresses are major barriers to the metastasis of
cancer cells. Autophagy-defective KRAS-driven lung
cancer cells exhibited impaired mitochondrial energy
homoeostasis, oxidative stress and a constitutively active
DNA damage response that were further mediated by
p53 and that triggered apoptosis in malignant cells, sug-
gesting that autophagy may play an important role in
the maintenance of mitochondrial function and in the
clearance of unfavorable factors the induce cell death,
thus promoting tumor progression [101,102]. Autophagy
may also promote the survival of HCC under hypoxic
conditions via the activation of mitochondrial β-oxidation
and intracellular ATP production [103].
Disseminated tumor cells that are unable to form firm
ECM contacts in a foreign microenvironment may trans-
form to enter dormancy [104], which may allow the
tumor cells to survive for years or decades at distant
sites without developing into secondary tumors while
retaining the ability to metastasize under the appropriate
conditions. Lu et al. reported that the tumor suppressor
aplasia Ras homolog member I (ARHI) induced autoph-
agy and enhanced the survival of dormant tumor cells
in vivo, demonstrating an association between autophagy
and the regulation of cancer cell dormancy for the first
time [105]. Therefore, it is possible that the partially dis-
seminated tumor cells that cannot successfully establish
an interaction with the ECM may initiate autophagy,
which drives the tumor cells into dormancy and pro-
motes their survival.
Cancer stem cells (CSCs) are characteristically resistant
to conventional anticancer therapy, which may contribute
to treatment failure and tumor relapse. CSCs exhibit the
potential to regenerate for an indefinite period, which may
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been shown to be a critical factor for CSC survival and
drug resistance [107,108]. Malignant breast tissue contains
a rare population of multi-potent cells exhibiting the cap-
acity to self-renew; these cells are defined as CSCs. These
mammary CSCs can propagate in culture as floating
spherical colonies termed ‘mammospheres’. The key au-
tophagy protein Beclin 1 was more strongly expressed in
mammospheres established from human breast cancer
samples or cell lines than in the parental adherent cells,
resulting in a higher level of autophagy in mammospheres.
This prosurvival autophagic flux was important for CSC
maintenance and tumor progression [108]. In addition,
one group reported that HIF-1a and autophagy played a
role in modulating the conversion of non-stem pancreatic
cancer cells to stem cells. This result suggested a role of
HIF-1a and autophagy in sustaining the dynamic equilib-
rium between CSCs and non-CSCs [109]. The relation-
ships between autophagy and cancer metastasis are
depicted in Figure 1.
Necroptosis and metastasis
Necrosis was originally considered to be an accidental
and unregulated cell death. Accumulating evidence has
shown that necrosis can be induced and proceed in a
regular manner like apoptosis, although in a caspase-Autopha
Pro-metastati
Anti-metastat
Autophagy reduces hypoxia-
induced tumor necrosis thus 
precludes inflammatory cells 
infiltration into tumor, resulting 
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Figure 1 Contradictory effects of autophagy on cancer metastasis. Th
mechanisms of autophagy, and the text in the yellow boxes depicts the po
high-mobility group B1; TLR4, Toll-like receptor 4; CSCs, cancer stem cells.independent fashion. Regulated necrosis is termed “pro-
grammed necrosis” or “necroptosis” to distinguish it
from necrosis caused by physical trauma [110]. Necrop-
tosis can be induced by the activation of the TNF recep-
tor superfamily [111], T cell receptors [112], interferon
receptors [113], Toll-like receptors (TLRs) [114], cellular
metabolic and genotoxic stresses, or various anti-cancer
agents. It can be pharmacologically inhibited by chemical
compounds such as necrostatin-1 (Nec-1) [115]. The for-
mation of the “necrosome” by receptor-interacting protein
kinase 1 (RIP1) and RIP3 is one of the most critical char-
acteristics of necroptosis. It is a multi-step process that
contains three key checkpoints. For example, in TNF-α
mediated necroptosis [110], at the first checkpoint, the E3
ligases cellular inhibitor of apoptosis 1 (cIAP1) and cIAP2
induce RIP1 ubiquitination [116], which blocks necropto-
sis via NF-κB-dependent or -independent mechanisms.
The removal of ubiquitin chains from RIP1 by the deubi-
quitinase cylindromatosis (CYLD) is critical for the pack-
aging of Complex IIa (including caspase-8, FADD, and
RIP1) and Complex IIb [(including caspase-8, FADD, RIP1,
RIP3, and mixed lineage kinase domain-like (MLKL)] [117].
At the second checkpoint, activated caspase-8 cleaves
and abolishes the activities of RIP1, RIP3, and CYLD
[118-120]. Cleaved RIP1 and RIP3 lose their capabilities
of trans-phosphorylation and downstream substrategy
c roles
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ruption of RIP1 and RIP3 is prevented by caspase-8 in-
hibitors (i.e., zVAD) or by the genetic inhibition of
caspase-8 or FADD, the trans-phosphorylation of RIP1
and RIP3 promotes their aggregation into the filamentous-
like necrosome [110]. MLKL is further phosphorylated by
RIP3 and is recruited to the necrosome by its interaction
with RIP3 [121]. MLKL forms a homotrimer via its amino-
terminal coiled-coil domain and translocates to the plasma
membrane during TNF-induced necroptosis, which leads
to necrotic plasma membrane permeabilization [122]. In
addition to MLKL, phosphoglycerate mutase 5 (PGAM5)
is a downstream substrate of RIP3 [123].
Several molecules and pathways contribute to the exe-
cution of TNF receptor-mediated necroptosis. Some of
these effectors are also involved in other receptor-
mediated necroptosis pathways [124]. During the pro-
gression of necroptosis, ROS are generated [125,126],
resulting in lipid peroxidation and increased mitochon-
drial membrane permeability. The cytosolic ATP levels
are sharply reduced due to the attenuation of ATP trans-
port from the mitochondria to the cytosol and ATP con-
sumption by over-active poly(ADP-ribose) polymerase 1
(PARP1). Apoptosis-inducing factor (AIF) is released
from mitochondria due to the increase in the mitochon-
drial membrane permeability and enters the nucleus to
cleave DNA. Lysosomal membrane permeabilization
(LMP) also occurs during necroptosis, resulting in the
leakage of cytotoxic hydrolases into the cytosol [124]. In
addition, dynamin-related protein l (Drp1), which acts
downstream of PGAM5, is thought to regulate mito-
chondrial fission to execute necroptosis [123].
Necroptosis plays an indispensable role during normal
development. Moreover, it has been implicated in the
pathogenesis of a variety of human diseases, including
cancer [127]. The necroptosis machinery is often im-
paired during tumorigenesis and tumor progression. For
example, chronic lymphocytic leukemia (CLL) cells
failed to undergo necroptosis upon stimulation using
TNFα combined with the pan-caspase inhibitor zVAD.
Two key components of necroptotic machinery, RIP3
and CYLD, were markedly downregulated in CLL [128].
In non-Hodgkin lymphoma, single nucleotide polymor-
phisms (SNPs) in the RIP3 gene were detected in 458
patients and correlated with increased risk of non-
Hodgkin lymphoma, which indicates that genetic varia-
tions in the RIP3 gene may contribute to the onset of
this disease [129]. There is a growing list of compounds
and anticancer agents that have been shown to induce
necroptosis in cancer cells. Shikonin was the first re-
ported small molecule that induced necroptosis [130].
Numerous studies have shown that shikonin and its ana-
logs not only are highly tumoricidal but also exhibit the
ability to bypass drug resistance machineries [130-133].In addition, compounds such as 5-benzylglycinyl-amiloride,
obatoclax, and D-galactose employ necroptosis to kill ma-
lignant cells [134-136]. Notably, some traditionally pro-
apoptotic anti-cancer agents have recently been demon-
strated to share the ability to induce the necroptosis of
tumor cells under certain circumstances. For example,
interferon-β-armed oncolytic adenovirus (ZD55-IFN-β) in-
duced both apoptosis and necroptosis in cancer cells. How-
ever, Nec-1 treatment converted ZD55-IFN-β-induced
necroptosis to apoptosis [137]. In addition, although
TRAIL is a well-known apoptosis inducer, one study
showed that acidic extracellular pH converted TRAIL-
induced apoptosis to necroptosis in human HT29 colon
and HepG2 liver cancer cells via a process that involved
RIPK1/RIPK3-dependent PARP-1 activation [138].
To date, few studies have associated necroptosis with
metastasis. Fu et al. reported that shikonin greatly re-
duced the lung metastasis of osteosarcoma by inducing
RIP1- and RIP3-dependent necroptosis [132]. The in-
duction of a high level of ROS via necroptosis may rep-
resent one factor that restricts cancer cell metastasis
[139]. As we have described above, metastatic cells in
the circulation or at new sites must survive in an envir-
onment without interacting with the ECM; under these
conditions, tumor cells face major difficulties in main-
taining nutrient and energy equilibration and in antag-
onizing metabolic stresses, especially ROS. Disseminated
tumor cells have evolved different strategies to restore
their ATP levels and to restrict cellular ROS production,
including the over-activation of pro-survival signals
(such as PI3K, Ras-ERK, and NF-κB), the enhancement
of antioxidant activity, the altered activation of metabolic
pathways (preferentially the glycolysis and pentose phos-
phate pathways), and the initiation of autophagy. However,
necroptosis represents another mechanism to eliminate
metastatic cancer cells by triggering ROS bursts. RIP3 has
been observed to be critical for regulating ROS production
during necroptosis [126], and this finding is in agreement
with another study showing that RIP3 activates several
metabolic enzymes [including glycogen phosphorylase
(PYGL), glutamate-ammonia ligase (GLUL), and glutam-
ate dehydrogenase 1 (GLUD1)] to regulate TNF-induced
ROS production. Silencing each of these enzymes results
in decreased levels of ROS accumulation and cell death
[125]. Therefore, it appears to be reasonable that necrop-
tosis is an important mechanism that restricts tumor me-
tastasis. In this case, tumor cells must overcome both
anoikis and necroptosis to successfully metastasize.
Interaction between apoptosis, autophagy, necroptosis,
and cancer metastasis
Programmed cell death in vivo involves the complex
interaction between apoptosis, autophagy, and necropto-
sis [140]. In some cases, a specific stimulus triggers only
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tions, the same stimulus may initiate multiple cell death
processes. Different types of mechanisms may co-exist
and interact with each other within a cell, but ultimately,
one mechanism dominates the others. The decision
taken by a cell to undergo apoptosis, autophagy, or
necroptosis is regulated by various factors, including the
energy/ATP levels, the extent of damage or stress, and
the presence of inhibitors of specific pathways (e.g., cas-
pase inhibitors). ATP depletion activates autophagy.
However, if autophagy fails to maintain the energy levels,
necroptosis occurs [141]. Slight/moderate damage and
low levels of death signaling typically induce apoptosis,
whereas severe damage and high levels of the death sig-
naling often result in necroptosis [142]. Although apop-
tosis is often the first mode of cell death and although
necroptosis is triggered only as a backup mechanism to
ensure that cell death occurs, emerging evidence has
shown that the necroptotic pathway may predominate
under certain pathological conditions [142]. The com-
plex relationships between different types of cell death
and cancer metastasis are depicted in Figure 2.
In the course of cancer metastasis, malignant cells
must overcome a series of unfavorable conditions, in-
cluding detachment from the ECM, attack by immune
cells, hypoxia and a growth factor-lacking environment,
which cause increased cellular ROS production andApoptosis
Autopha
Metastatic 
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Figure 2 Interaction between different types of programmed cell dea
many unfavorable conditions, including detachment from the ECM, attack
cause increased cellular ROS production and DNA damage and insufficient
high levels of death signals often result in necroptosis. Due to the activity
cells from the primary tumor cannot successfully macrometastasize. Compa
capricious, as on one hand, autophagy greatly improves the fitness of meta
necroptosis, but on the other hand, autophagy reduces metastasis by restr
infiltration. Additionally, excess autophagy induces the death of metastasiziDNA damage and an insufficient energy status. There-
fore, most metastatic cells from the primary tumor are
unable to successfully macrometastasize and are killed
via apoptosis or necroptosis. On one hand, autophagy
greatly improves the fitness of cancer cells under stressful
conditions and, thus, attenuates apoptosis and necroptosis,
but on the other hand, autophagy antagonizes metastasis
by restricting tumor necrosis and subsequent immune cell
infiltration. Additionally, excess autophagy induces the
death of metastasizing cells. Therefore, the interaction
between different types of cell death and cancer metastasis
is highly complex. In addition, cancer cells have evolved
sophisticated mechanisms to antagonize apoptosis and
necroptosis. However, defects in the machinery of one
type of cell death may not affect that of another. Thus,
triggering a single type of programmed cell death may
not be sufficient for the treatment of cancer metastasis.
The selection of different cell death inducers or the
combined use of different cell death pathway inducers
will help to overcome drug resistance to kill metastatic
cells [140,143,144].
Conclusions and perspectives
Programmed cell death, are natural barriers that restrict
malignant cells from surviving and disseminating. How-
ever, cancer cells evolve various strategies to evade pro-
grammed cell death by generating genetic mutations orgy
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th and cancer metastasis. Disseminating metastatic cells must face
by immune cells, hypoxia or a growth factor-lacking environment, that
energy status. Low levels of death signals stimulate apoptosis, whereas
of the apoptosis (anoikis) and necroptosis machineries, most metastatic
red with apoptosis and necroptosis, autophagy appears to be fairly
static cells under stressful conditions to counteract apoptosis and
icting tumor necrosis and by precluding inflammatory immune cell
ng cells.
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grammed cell death pathways. The role of autophagy in
cancer metastasis is complex, as reports have indicated
both pro-metastatic and anti-metastatic roles of autoph-
agy. Stage-specificity may affect the cellular response to
autophagy during cancer metastasis. Programmed cell
death in vivo involves the complex interaction between
apoptosis, autophagy, and necroptosis. Different types of
mechanisms may co-exist and interact with each other
within a cell. The decision taken by a cell to undergo
apoptosis, autophagy, or necroptosis is regulated by vari-
ous factors, including the energy/ATP levels, the extent
of damage or stress, and the presence of inhibitors of
specific pathways.
In this review, we summarized how apoptosis, autoph-
agy, and necroptosis affect cancer metastasis based on
the current literature. However, still many issues remain
to be clarified.
(i) As we have discussed in this review, autophagy
plays a dual role in tumor metastasis. Generally speak-
ing, autophagy may exert an inhibitory effect during the
early step of cancer metastasis by, for example, restrict-
ing necrosis and inflammation and by preventing
oncogene-induced senescence, thereby limiting the inva-
sion and dissemination of cancer cells from the primary
site. Alternatively, autophagy tends to promote metasta-
sis during advanced cancer stages by supporting ECM-
detached metastatic cell survival and colonization at a
distant site and by inducing metastatic cells to enter dor-
mancy if they fail to establish a contact with the ECM in
the new environment. As a delicate process, autophagy
may play either pro- or anti-metastatic roles depending on
the context. At present, the complex role of autophagy in
metastasis remains unclear. It is necessary to determine
how the dual role of autophagy in metastasis is regulated;
i.e., what are the signals, molecules, and mechanisms that
enable autophagy to play a dominant anti-metastatic role
in one situation an opposite role in another situation.
(ii) At present, we know very little about the roles of
necroptosis in cancer progression. As we have men-
tioned above, the necroptosis machinery may be im-
paired during tumorigenesis and tumor progression. For
example, CLL leukemia cells failed to undergo necropto-
sis due to the downregulation of RIP3 and CYLD [128].
In non-Hodgkin lymphoma, genetic variations in the
RIP3 gene were detected in 458 patients and correlated
with increased risk of non-Hodgkin lymphoma [129].
However, according to our study (unpublished) using a
series of cancer cell lines, only a small proportion (ap-
proximately 10%) of cancer cells undergo necroptosis in
response to stimuli. It is necessary to determine why so
many cancer cells lose their necroptotic machinery and
the importance of this machinery in regulating tumori-
genesis and cancer metastasis.(iii) It is necessary to investigate the relationship be-
tween programmed cell death and cancer metastasis in
the tumor microenvironment, including the tumor-
infiltrating immune cells. For example, preclinical evi-
dence has shown that chemotherapy-induced autophagy
in cancer cells may contribute to the recruitment of mye-
loid cells to the tumors and the subsequent T lymphocyte-
mediated suppression of tumor growth [145]. In addition,
programmed cell death plays critical roles in the mainten-
ance of proper innate and adaptive immune function
[146]. Therefore, dysfunction of the programmed cell
death machinery in the immune system may change its ef-
fect on cancer growth and metastasis. This evidence sug-
gests that programmed cell death should be investigated
simultaneously in both cancer cells and immune cells to
understand the interaction between these cell types.
(iv) The regulation of programmed cell death and me-
tastasis by non-coding RNAs (ncRNAs) is a novel direc-
tion of this research field. ncRNAs include multiple
classes of RNA transcripts that are not translated into
proteins but can regulate the transcription, stability or
translation of protein-coding genes in the mammalian
genome [147]. The most studied ncRNAs are micro-
RNAs (typically consisting of 19–24 nucleotides), which
are highly conserved small ncRNA molecules that func-
tion to regulate a wide variety of cellular processes by
interfering with protein expression or mRNA degrad-
ation. Numerous miRNAs have been reported to be in-
volved in the regulation of programmed cell death or
cancer progression [148,149]. More recently, long none-
coding RNAs (lncRNAs) have been found to play critical
roles in transcriptional and translational regulation [150]
and have been implicated in a wide range of human dis-
eases, including cancer [151]. Some lncRNAs have been
observed to target the apoptotic and autophagy pathways
and to play a role in cancer development. For example,
MEG3 inhibited the proliferation and induced the apop-
tosis of NSCLC cells by affecting p53 expression [152],
and GAS5 regulated the apoptosis of NSCLC cells [153].
In addition, HULC was overexpressed in human gastric
cancer (GC) cell lines and tissues compared with normal
controls, and this overexpression correlated with lymph
node metastasis, distant metastasis and advanced tumor
node metastasis stage. Further investigation showed that
HULC-induced autophagy was a major reason for GC cell
survival and metastasis [154]. At present, the regulation of
programmed cell death and cancer metastasis by ncRNAs,
especially lncRNAs, remains largely unknown, and further
investigation is required to clarify their mechanisms.
The more we understand the specific roles, mecha-
nisms, and regulators of apoptosis, autophagy, and
necroptosis and their interaction with cancer metasta-
sis, the better therapeutic strategies can be developed
for cancer treatment.
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